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Peroxisomes are catalase-containing subcellular organelles which play a role in 
lipid metabolism. Patients with peroxisomal disorders lack the membrane-bound 
peroxisomal enzyme, dihydroxyacetonephosphate acyltransferase (DHAP-AT), 
which catalyses the first step in the biosynthesis of plasmalogens (Datta et al., 1984; 
Schutgens et al., 1984). However, the distal enzymes of plasmalogen synthesis have 
significant activity in fibroblasts of patients with Zellweger syndrome (Schrakamp 
et al., 1985) and incorporation of alkylglycerols into plasmalogens proceeds nor- 
mally in these fibroblasts. Since dietary 1-alkylglycerols are absorbed intact 
(Blomstrand, 1959), dietary supplementation with plasmalogen precursors offers 
potential therapy for treating patients with peroxisomal disorders. We present the 
results of administering alkylglycerols to two patients with decreased DHAP-AT 
activity and low levels of erythrocyte plasmalogens. 
CASE HISTORIES 
Case 1 
This 3½-year-old-boy was briefly described in a prior report (Wilson et al., 1986). 
He was the product of a term uncomplicated gestation. Enlarged anterior and 
posterior fontanelles, open metopic suture and a widened sagittal suture were 
present at birth. He was admitted at age 7 weeks for evaluation of poor weight 
gain, hypotonia and hepatomegaty. Laboratory investigation revealed anaemia 
and elevation of the serum bilirubin, alkaline phosphatase, SGPT and ferritin. 
Percutaneous liver biopsy showed increased glycogen with fibrous septa and paucity 
of intrahepatic ducts. At age 9 months ophthalmological evaluation showed incon- 
sistent fixation and following of light, vertical nystagmus, bilateral punctate cortical 
and nuclear sclerosis lens changes with no cataracts, and marked peripheral retinal 
pigmentary changes. Visual evoked response and electroretinogram showed no 
photopic or scotopic responses suggesting a poor outlook for vision. 
Assays for DHAP-AT and plasmalogens performed at age 14 months were 
abnormal and he was started on oral ether lipid supplementation. After 3 months 
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of treatment there was improved growth and muscle tone, decreased nystagmus 
and improved ability to follow light and fixate. Fundoscopic examination showed 
virtual disappearance of retinal pigmentation. 
He has continued to improve and attends special education school. Visual acuity 
has not been measured but he can avoid obstructions while walking and walks 
towards and reaches for toys. 
Case 2 
This 4-year-old girl was delivered at term by caesarean section because of maternal 
eclampsia and weighed 2.7 kg. Routine neonatal screening of serum thyroxin was 
low and thyroid replacement therapy was begun. She was a poor feeder with poor 
weight gain and at age 6 months was admitted for evaluation of failure to thrive 
and developmental delay. Clinical findings included hepatomegaly, ascites and 
pericardial effusion. Total serum proteins were low and values of SGOT and 
SGPT were elevated. Percutaneous liver biopsy revealed periportal fibrosis and 
accumulation of glycogen. The ascites resolved and she was discharged. 
At age 2½ years she was re-evaluated because of developmental delay, failure to 
thrive, hypotonia, seizures and hepatomegaly. She was euthyroid, but assays for 
DHAP-AT activity and erythrocyte plasmalogens were abnormal. Oral ether lipid 
treatment was begun. 
After 18 months of therapy her muscle tone and general state of awareness have 
improved. She is able to walk and is auditorially and visually alert. Sequential 
developmental and psychomotor evaluations in a special education programme 
have shown progress in social/emotional, cognitive, language and motor skills. 
MATERIALS AND METHODS 
Assays for DHAP-AT activity were performed as described by Datta and colleagues 
(1984). Plasmalogens were measured as previously described (Wilson et al., 1986). 
Very long chain fatty acids in plasma were fractionated and quantitated by the 
method of Moser and colleagues (1984). 
The ether lipid mixture contains 400 mg of batyl alcohol and 200 mg of sodium 
deoxycholate in 100mL of water. Each patient has been receiving 5 mL of this 
suspension daily, equivalent to 20 mg batyl alcohol per day for the past year. Prior 
to that they had been receiving an ether lipid suspension containing batyl alcohol, 
chimyl alcohol and selachyl alcohol as previously described (Wilson et al., 1986). 
RESULTS 
Fibroblast DHAP-AT activity in patient 1 was 0.14 nmol min -1 (mg protein) -1 and 
0.12 nmol min -a (mg protein) -a in case 2. Each patient had approximately 50% of 
control activity. 
Erythrocyte phosphoethanolaminc plasmalogen composition in patient t at age 
14 months just prior to starting treatment was 4% of total phospholipids (control 
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10%). Following treatment the levels have been: 7.9% (age 20 months), 9.8% (age 
25 months), and 10% (age 33 months). The level in patient 2 prior to treatment 
was 1.3% (age 30 months), and following treatment has been 11.1% (age 34 
months) and 11.2% (age 46 months). 
Very long chain fatty acids were elevated in the plasma of patient 1 and were 
normal in patient 2. Repeat levels in patient 1 did not change during treatment. 
DISCUSSION 
Administration of oral ether lipids represents a potential treatment for patients with 
peroxisomal disorders and the multiple consequences of peroxisome deficiency. 
Although both of our patients are clinically improving and their erythrocyte 
phosphoethanolamine plasmalogen composition has returned to control levels, the 
efficacy of ether lipid therapy is not clear. Comprehensive therapy for patients with 
peroxisomal defects has not been determined, and severely affected patients may 
not be amenable to treatment. 
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